标题: |
肝细胞癌免疫治疗中国临床专家共识(2021版) |
title: |
Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma(2021) |
版本: |
原创版 |
version: |
Original |
分类: |
专家共识 |
classification: |
Experts consensus |
领域: |
治疗 |
field: |
Treatment |
国家和地区: |
中国 |
Country and
region:
|
China |
指南使用者: |
医生 |
Guide users:
|
Doctor |
证据分级方法: |
证据级别 描述
Ia 证据源于对多项随机对照研究的Meta分析结果
Ib 证据源于至少一项设计良好的随机对照研究结果
IIa 证据源于至少一项设计良好的前瞻性非随机对照研究结果
IIb 证据源自至少一项设计良好的其他类型干预性临床研究结果
III 证据源于设计良好的非干预性研究,如描述性研究、相关性研究等
IV 证据源于专家委员会报告或权威专家的临床经验报道 |
Evidence grading
method:
|
IA evidence derived from Meta-analysis results of multiple randomized controlled studies
IB evidence derived from at least one well-designed randomized controlled study
IIA evidence derived from at least one well-designed prospective non-randomized controlled study
IIB evidence derived from at least one well-designed other type of intervention clinical study
III evidence derived from a well-designed non-intervention study, such as descriptive studies, Correlation Studies and other
IV evidence from Expert Committee reports or authoritative clinical experience of experts reported |
制定单位: |
中国医师协会肝癌专业委员会 |
Formulating unit: |
Chinese Association of Liver Cancer |
注册时间: |
2022-03-06 |
Registration time: |
注册编号: |
IPGRP-2022CN108 |
Registration number: |
指南制订的目的: |
规范肝细胞癌的免疫治疗 |
Purpose of the guideline:
|
To standard the immunotherapy for hepatocellular carcinoma(HCC) |